Q-omics provides the consensus-scored HEATR6 profile across patient tissues and cancer cell-line models. HEATR6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, HEATR6 is differentially expressed in 16, with the highest sampling consensus in KIRP. Additionally, HEATR6 RNA expression shows 20,112 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight STAD, KIRP, and ACC as cancer lineages where HEATR6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HEATR6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HEATR6 survival associations across molecular data types. HEATR6 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HEATR6 RNA expression–survival associations across cancer types. High HEATR6 expression shows unfavorable associations in STAD, LIHC, KIRC, KIRP, MESO and KICH. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for HEATR6 RNA expression.
This table summarizes HEATR6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HEATR6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HEATR6 shows higher tumor expression in KIRP, HNSC, LUAD, LIHC, KIRC and BRCA. The KIRP box plot shows higher HEATR6 RNA expression in tumor versus normal tissue (log2 FC = +1.597, t-test p < 0.001).
This table shows molecular features associated with HEATR6 in patient tissues and cancer cell lines. In patient samples, HEATR6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, HEATR6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
